Literature DB >> 33237528

Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells.

V Kh Khavinson1,2, N S Linkova3,4, I M Kvetnoy1, V O Polyakova1, A O Drobintseva1, T V Kvetnaia1, O M Ivko1.   

Abstract

Thymalin is a polypeptide complex isolated from the thymus and regulating the functions of the immune system. Thymalin is effective in therapy of acute respiratory syndrome, chronic obstructive bronchitis, and other immunopathology. Thymalin increases functional activity of T lymphocytes, but the targeted molecular mechanism of its biological activity requires further study. We studied the influence of thymalin on differentiation of human hematopoietic stem cells (HSC) and expression of CD28 molecule involved in the implementation of antiviral immunity in COVID-19 infection. It was found that thymalin reduced the expression of CD44 (stem cell marker) and CD117 (molecule of the intermediate stage of HSC differentiation) by 2-3 times and increased the expression of CD28 (marker of mature T lymphocytes) by 6.8 times. This indirectly indicates that thymalin stimulated differentiation of CD117+ cells into mature CD28+T lymphocytes. It is known that in patients with severe COVID-19, the number of CD28+, CD4+, CD8+T lymphocytes in the blood decreased, which attested to a pronounced suppression of immunity. It is possible that the antiviral effect of thymalin consists in compensatory stimulation of HSC differentiation into CD28+T lymphocytes at the stage of immunity suppression in unfavorable course of viral infection. Thymalin can be considered as an immunoprotective peptide drug for the prevention of COVID-19.

Entities:  

Keywords:  COVID-19; cell differentiation; hematopoietic stem cells; peptides; thymalin

Mesh:

Substances:

Year:  2020        PMID: 33237528      PMCID: PMC7686446          DOI: 10.1007/s10517-020-05016-z

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  15 in total

1.  Thymalin in developing respiratory organs of human fetus.

Authors:  Z S Khlystova; I I Kalinina; S P Shmeleva
Journal:  Bull Exp Biol Med       Date:  2003-06       Impact factor: 0.804

2.  The laboratory tests and host immunity of COVID-19 patients with different severity of illness.

Authors:  Feng Wang; Hongyan Hou; Ying Luo; Guoxing Tang; Shiji Wu; Min Huang; Weiyong Liu; Yaowu Zhu; Qun Lin; Liyan Mao; Minghao Fang; Huilan Zhang; Ziyong Sun
Journal:  JCI Insight       Date:  2020-05-21

3.  Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells.

Authors:  Renier Myburgh; Jonathan D Kiefer; Norman F Russkamp; Chiara F Magnani; Nicolás Nuñez; Alexander Simonis; Surema Pfister; C Matthias Wilk; Donal McHugh; Juliane Friemel; Antonia M Müller; Burkhard Becher; Christian Münz; Maries van den Broek; Dario Neri; Markus G Manz
Journal:  Leukemia       Date:  2020-05-01       Impact factor: 11.528

4.  Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo.

Authors:  G V Zhukova; A I Schikhlyarova; T A Barteneva; A N Shevchenko; F M Zakharyuta
Journal:  Bull Exp Biol Med       Date:  2018-05-24       Impact factor: 0.804

Review 5.  Peptide Regulation of Cell Differentiation.

Authors:  Vladimir Khavinson; Natalia Linkova; Anastasiia Diatlova; Svetlana Trofimova
Journal:  Stem Cell Rev Rep       Date:  2020-02       Impact factor: 5.739

Review 6.  CD44: More than a mere stem cell marker.

Authors:  I Morath; T N Hartmann; V Orian-Rousseau
Journal:  Int J Biochem Cell Biol       Date:  2016-09-15       Impact factor: 5.085

7.  Differences in T regulatory cells between mouse strains frequently used in immunological research: Treg cell quantities and subpopulations in NOD, B6 and BALB/c mice.

Authors:  Gloria J Godoy; Daniela A Paira; Carolina Olivera; Maria L Breser; Leonardo R Sanchez; Ruben D Motrich; Virginia E Rivero
Journal:  Immunol Lett       Date:  2020-04-21       Impact factor: 3.685

Review 8.  Current pharmacological treatments for COVID-19: What's next?

Authors:  Cristina Scavone; Simona Brusco; Michele Bertini; Liberata Sportiello; Concetta Rafaniello; Alice Zoccoli; Liberato Berrino; Giorgio Racagni; Francesco Rossi; Annalisa Capuano
Journal:  Br J Pharmacol       Date:  2020-05-15       Impact factor: 8.739

9.  PD-1 blockade-unresponsive human tumor-infiltrating CD8+ T cells are marked by loss of CD28 expression and rescued by IL-15.

Authors:  Kyung Hwan Kim; Hong Kwan Kim; Hyung-Don Kim; Chang Gon Kim; Hoyoung Lee; Ji Won Han; Seong Jin Choi; Seongju Jeong; Minwoo Jeon; Hyunglae Kim; Jiae Koh; Bo Mi Ku; Su-Hyung Park; Myung-Ju Ahn; Eui-Cheol Shin
Journal:  Cell Mol Immunol       Date:  2020-04-24       Impact factor: 11.530

10.  COVID-19: consider cytokine storm syndromes and immunosuppression.

Authors:  Puja Mehta; Daniel F McAuley; Michael Brown; Emilie Sanchez; Rachel S Tattersall; Jessica J Manson
Journal:  Lancet       Date:  2020-03-16       Impact factor: 79.321

View more
  1 in total

1.  Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19.

Authors:  V Kh Khavinson; B I Kuznik; S V Trofimova; V A Volchkov; S A Rukavishnikova; O N Titova; T A Akhmedov; A V Trofimov; V V Potemkin; E Magen
Journal:  Stem Cell Rev Rep       Date:  2021-02-11       Impact factor: 5.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.